TNFRSF8 and Hodgkins lymphoma: CD30 has been implicated as an excellent potential target for the treatment of HL and ALCL with the data presented previously (Fanale et al., 2012; Francisco et al., 2003; Gopal et al., 2015; Pro et al., 2012).